FibroBiologics, Inc.
FBLG
$0.35
$0.025.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -24.04% | 6.20% | -60.25% | -519.80% | -155.68% |
| Total Depreciation and Amortization | 12.14% | 27.95% | 5.23% | 6.99% | 2.14% |
| Total Amortization of Deferred Charges | -100.00% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 371.12% | -70.32% | 613.82% | 106.89% | 36.05% |
| Change in Net Operating Assets | 112.11% | 69.20% | -457.35% | -534.09% | -109.50% |
| Cash from Operations | 0.30% | 24.47% | -71.66% | -17.92% | -33.85% |
| Capital Expenditure | 97.18% | -395.35% | 56.57% | -800.00% | 83.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 97.18% | -395.35% | 56.57% | -800.00% | 83.33% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 33.14% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -99.03% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -- | -- | 108.68% | 2,699.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,334.83% | 103.35% | -186.36% | 232.15% | 184.85% |